Avacta Group Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Avacta GroupDer Gewinn des Unternehmens wird voraussichtlich um 2.1% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 0.4% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich wachsen um 15% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -73.3% betragen.

Wichtige Informationen

-2.1%

Wachstumsrate der Gewinne

15.0%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	37.0%
Wachstumsrate der Einnahmen	0.4%
Zukünftige Eigenkapitalrendite	-73.3%
Analystenabdeckung	Low
Zuletzt aktualisiert	21 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Avacta Group Plc's (LON:AVCT) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Nov 19

Is Avacta Group (LON:AVCT) Using Debt Sensibly?

Oct 29

Avacta Group Plc's (LON:AVCT) 29% Share Price Surge Not Quite Adding Up

Sep 05

Improved Revenues Required Before Avacta Group Plc (LON:AVCT) Shares Find Their Feet

Jun 21

This Is The Reason Why We Think Avacta Group Plc's (LON:AVCT) CEO Deserves A Bump Up To Their Compensation

Jun 22

Avacta Group (LON:AVCT) Is In A Good Position To Deliver On Growth Plans

Jun 20

Avacta Group Plc (LON:AVCT) Insiders Have Been Selling

Feb 18

Gewinn- und Umsatzwachstumsprognosen

AIM:AVCT - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (GBP Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	22	-29	-26	-20	3
12/31/2025	27	-35	-28	-23	4
12/31/2024	24	-36	-29	-22	4
6/30/2024	23	-26	-21	-19	N/A
3/31/2024	23	-25	-18	-17	N/A
12/31/2023	23	-25	-16	-15	N/A
9/30/2023	20	-32	-16	-15	N/A
6/30/2023	16	-40	-16	-15	N/A
3/31/2023	13	-38	-16	-16	N/A
12/31/2022	10	-37	-17	-16	N/A
9/30/2022	8	-31	-19	-18	N/A
6/30/2022	7	-25	-21	-20	N/A
3/31/2022	5	-26	-21	-20	N/A
12/31/2021	3	-26	-22	-21	N/A
6/30/2021	2	-20	-18	-16	N/A
3/31/2021	2	-18	-15	-14	N/A
12/31/2020	2	-16	-12	-11	N/A
6/30/2020	5	-12	-9	-8	N/A
3/31/2020	4	-12	-10	-9	N/A
12/31/2019	4	-11	-11	-9	N/A
7/31/2019	4	-10	-10	-8	N/A
4/30/2019	3	-10	-9	-6	N/A
1/31/2019	2	-10	-7	-5	N/A
10/31/2018	3	-9	-8	-5	N/A
7/31/2018	3	-9	-8	-5	N/A
4/30/2018	3	-8	N/A	-6	N/A
1/31/2018	3	-7	N/A	-6	N/A
10/31/2017	3	-7	N/A	-5	N/A
7/31/2017	3	-6	N/A	-4	N/A
4/30/2017	3	-6	N/A	-4	N/A
1/31/2017	2	-6	N/A	-5	N/A
10/31/2016	2	-5	N/A	-4	N/A
7/31/2016	2	-5	N/A	-4	N/A
4/30/2016	2	-5	N/A	-3	N/A
1/31/2016	2	-5	N/A	-3	N/A
10/31/2015	2	-5	N/A	-3	N/A
7/31/2015	2	-5	N/A	-3	N/A
4/30/2015	2	-4	N/A	-2	N/A
1/31/2015	2	-3	N/A	-2	N/A
10/31/2014	2	-2	N/A	-1	N/A
7/31/2014	2	-1	N/A	-1	N/A
4/30/2014	2	-1	N/A	-1	N/A
1/31/2014	2	-1	N/A	-1	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: AVCT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: AVCT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: AVCT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: AVCTDie Einnahmen des Unternehmens (0.4% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt UK (3.6% pro Jahr).

Hohe Wachstumseinnahmen: AVCTDie Einnahmen des Unternehmens (0.4% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: AVCT wird voraussichtlich in 3 Jahren unrentabel sein.

Avacta Group Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates upgraded to UK£0.09 loss

Price target decreased by 13% to UK£1.38

Price target decreased to UK£1.55

Price target decreased to UK£1.55

Price target decreased to UK£2.55

Recent updates

Consensus EPS estimates upgraded to UK£0.09 loss

Avacta Group Plc's (LON:AVCT) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Is Avacta Group (LON:AVCT) Using Debt Sensibly?

Avacta Reports Pipeline Advances with Two Novel Programs at the EORTC-NCI-AACR Molecular Targets Symposium in Barcelona

Avacta Group plc Expands Its Pipeline with Two Novel Assets Developed Using Its Pre|CISION Platform

Avacta Group plc Appoints Michelle Morrow as Chief Scientific Officer, Effective November 4, 2024

Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted Cancer Therapy Programs At 2024 Eortc-Nci-Aacr Symposium

First half 2024 earnings released: UK£0.038 loss per share (vs UK£0.043 loss in 1H 2023)

New major risk - Financial position

Avacta Group plc Reports Updated Phase 1 Data of Ava6000 At the European Society for Medical Oncology Congress Demonstrating Multiple Ongoing, Durable Responses in Solid Tumors

Avacta Group Plc to Report First Half, 2024 Results on Sep 30, 2024

Avacta Group Plc's (LON:AVCT) 29% Share Price Surge Not Quite Adding Up

CFO & Company Secretary exercised options and sold UK£305k worth of stock

Avacta Group plc Announces Board Changes

Improved Revenues Required Before Avacta Group Plc (LON:AVCT) Shares Find Their Feet

Avacta Group plc Announces Board Changes

Avacta Group Plc, Annual General Meeting, Jun 26, 2024

Avacta Group plc Announces Successful Completion of First Cohort and Dosing of Three Patients of the Second Cohort in Arm 2 of Avacta's Ava6000 Phase 1 Trial

Avacta Group plc Announces Chief Executive Officer Changes

Avacta Group plc Announces Chief Executive Officer Changes

Full year 2023 earnings: EPS misses analyst expectations

New minor risk - Financial data availability

Avacta Group plc Reports Data from the Ongoing Phase 1 Clinical Trial of AVA6000 At the AACR Annual Meeting

Avacta Group Plc Announces Update on AVA6000 Phase 1a Clinical Trial Progress

Avacta Group Plc has completed a Follow-on Equity Offering in the amount of £5.448474 million.

Avacta Group Plc has filed a Follow-on Equity Offering in the amount of AUD 20.560243 million.

Investors Give Avacta Group Plc (LON:AVCT) Shares A 26% Hiding

Avacta Group plc Announces Appointment of Christina Coughlin as Head of Research and Development and Resignation of Fiona Mclaughlin as Chief Scientific Officer

Avacta Group plc Appoints Simon Bennett as Chief Business Officer of the Therapeutics Division

Price target decreased by 13% to UK£1.38

Avacta Group plc Provides Detailed Pre-Clinical, Clinical and Pharmacokinetic Data from the Phase 1A Dose Escalation Study

First half 2023 earnings released: UK£0.043 loss per share (vs UK£0.036 loss in 1H 2022)

New major risk - Financial position

Avacta Group Plc Announces Management Changes

Avacta Group plc Announces Successful Completion of ALS-6000-101 Sixth Dose Escalation

Avacta Group Plc to Report First Half, 2023 Results on Sep 28, 2023

New minor risk - Share price stability

Getting In Cheap On Avacta Group Plc (LON:AVCT) Is Unlikely

Avacta Announces Successful Completion of Fifth Dose Escalation in Ava6000 Phase 1 Clinical Study

Would Avacta Group (LON:AVCT) Be Better Off With Less Debt?

Avacta Group plc Appoints Shaun Chilton to the Board as Non-Executive Director

Avacta Group Plc (AIM:AVCT) acquired Unknown minority stake in AffyXell Therapeutics Co., Ltd. from Daewoong pharmaceutical Co.,Ltd (KOSE:A069620).

Avacta Group Plc, Annual General Meeting, Jun 28, 2023

Avacta Group plc acquired Coris Bioconcept SRL for £10.4 million.

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Avacta Group plc Announces Successful Completion of Fourth Dose Escalation in AVA6000 Phase 1 Clinical Study

Price target decreased to UK£1.55

High number of new and inexperienced directors

Price target decreased to UK£1.55

Avacta Group Plc (AIM:AVCT) conditionally agreed to acquire Launch Diagnostics Holdings Limited for £37 million.

First half 2022 earnings released: UK£0.036 loss per share (vs UK£0.041 loss in 1H 2021)

Avacta Group Plc to Report First Half, 2022 Results on Sep 29, 2022

Avacta Group plc Announces Phase I Study of AVA6000 Advances to Fourth Cohort

High number of new and inexperienced directors

Avacta Group Plc announced that it has received funding

Avacta Group Plc Announces Second Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-Doxorubicin

Avacta Group Plc, Annual General Meeting, Jun 23, 2022

Avacta Group Plc Relocates its Therapeutics Division to New Headquarters at Scale Space, in Imperial College's White City Campus, London

Less than half of directors are independent

Full year 2021 earnings released: UK£0.11 loss per share (vs UK£0.084 loss in FY 2020)

Avacta Group Plc to Report Fiscal Year 2021 Results on Apr 06, 2022

Avacta Group Plc to Report Fiscal Year 2021 Results on Apr 06, 2022

Avacta Announces Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-Doxorubicin

Avacta Group plc Selects Second Pre|Cision™ Pro-Drug Candidate for Development

Avacta Group plc Provides Update on AffiDX SARS-CoV-2 Antigen Lateral Flow Test and Detection of the Omicron Variant

Avacta Group Plc Announces AffiDX® SARS-CoV-2 Antigen Lateral Flow Test Has Received A CE Mark for Use as A Consumer Self-Test in the UK and EU

Avacta Group Plc Announces AffiDx® SARS-CoV-2 Antigen Lateral Flow Test Detects the Omicron Variant

Avacta Group plc Announces US Food and Drug Administration Approval of IND Application for AVA6000

We're Hopeful That Avacta Group (LON:AVCT) Will Use Its Cash Wisely

First half 2021 earnings released: UK£0.041 loss per share (vs UK£0.037 loss in 1H 2020)